Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.

The oncologist - 1 Jan 2010

Shankaran Veena, Obel Jennifer, Benson Al B

Abstract excerpt

The identification of KRAS mutational status as a predictive marker of response to antibodies against the epidermal growth factor receptor (EGFR) has been one of the most significant and practice-changing recent advances in colorectal cancer research. Recently, data suggesting a potential role for other markers (including BRAF mutations, loss of phosphatase and tension homologue deleted on chromosome ten...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to ErbB Receptors
Share to Forecasting

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Mutation

Share to Neoplasm Metastasis

Share to Predictive Value of Tests

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 20133499
DOI: 10.1634/theoncologist.2009-0221
PMCID: PMC3227936

Genes

EGFR
KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.PMID 20133499Read ↗

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.Semantic proximity Read ↗

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.Semantic proximity Read ↗

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].Semantic proximity Read ↗

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.